PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION

被引：0

作者：

TURA, S ^{[1
]}

RUSSO, D ^{[1
]}

FANIN, R ^{[1
]}

ZUFFA, E ^{[1
]}

PATRIARCA, F ^{[1
]}

FIACCHINI, M ^{[1
]}

BACCARANI, M ^{[1
]}

TESTONI, N ^{[1
]}

ZAMAGNI, MD ^{[1
]}

ZACCARIA, A ^{[1
]}

MONTEFUSCO, E ^{[1
]}

ALIMENA, G ^{[1
]}

MELONI, G ^{[1
]}

MANDELLI, F ^{[1
]}

DAMIANI, D ^{[1
]}

MICHIELI, M ^{[1
]}

SILVESTRI, F ^{[1
]}

VIRGOLINI, L ^{[1
]}

CRISCUOLO, D ^{[1
]}

FOWST, C ^{[1
]}

HOLDENER, EE ^{[1
]}

SPECCHIA, G ^{[1
]}

LISO, V ^{[1
]}

MORRA, E ^{[1
]}

BERNASCONI, C ^{[1
]}

DEMILIO, A ^{[1
]}

BATTISTA, R ^{[1
]}

DITUCCI, A ^{[1
]}

BROCCIA, G ^{[1
]}

MAJOLINO, I ^{[1
]}

CARONIA, F ^{[1
]}

LUCIANO, L ^{[1
]}

ROTOLI, B ^{[1
]}

LEONI, P ^{[1
]}

BODENIZZA, CA ^{[1
]}

CAROTENUTO, M ^{[1
]}

ROTONDO, SG ^{[1
]}

NOSARI, A ^{[1
]}

DECATALDO, F ^{[1
]}

MONTUORO, A ^{[1
]}

DELAURENZI, A ^{[1
]}

LIBERATI, AM ^{[1
]}

TABILIO, A ^{[1
]}

MARTELLI, M ^{[1
]}

RAMBALDI, A ^{[1
]}

BARBUI, T ^{[1
]}

LEONI, F ^{[1
]}

CIOLLI, S ^{[1
]}

RONCA, F ^{[1
]}

NOBILE, F ^{[1
]}

机构：

[1] UNIV BOLOGNA,IST EMATOL SERAGNOLI,I-40126 BOLOGNA,ITALY

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

CHRONIC MYELOID LEUKEMIA; PROGNOSIS; BONE MARROW TRANSPLANTATION; INTERFERON;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate the prognostic features of Ph+ CML patients treated by allogeneic BMT or by IFN, we reviewed the data of 50 consecutive pts who were transplanted between 1984 and 1988 and of 180 consecutive patients who were assigned to continuous IFN treatment between 1986 and 1988. In the BMT group, Sokal's system predicted survival (transplant-associated mortality). In the IFN group, Sokal's system, platelet count, and peripheral blood blast cell percentage predicted karyotypic response. In this group, survival was related more significantly with blast cell than with Sokal's score. The strongest predictor of survival was karyotypic response to IFN, with a 4-year survival of 94% for responders vs. 56% for non-responders.

引用

页码：67 / 71

页数：5

共 50 条

[1] BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA
APPERLEY, JF
GOLDMAN, JM
PLASMA THERAPY & TRANSFUSION TECHNOLOGY, 1985, 6 (02): : 207 - 220
[2] BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA
SPECK, B
GRATWOHL, A
OSTERWALDER, B
NISSEN, C
SEMINARS IN HEMATOLOGY, 1984, 21 (01) : 48 - 52
[3] BONE-MARROW TRANSPLANTATION IN CHRONIC MYELOID-LEUKEMIA
PORCELLINI, A
IZZI, T
DELFINI, C
POLCHI, P
GALIMBERTI, M
MORETTI, L
MANNA, A
BOCCONCELLI, A
LUCARELLI, G
EXPERIMENTAL HEMATOLOGY, 1984, 12 (06) : 447 - 447
[4] BONE-MARROW TRANSPLANTATION IN CHRONIC MYELOID-LEUKEMIA
DEVERGIE, A
GLUCKMAN, E
VARRIN, F
HURET, JL
MELETIS, J
DECASTRO, H
BOMBAIL, D
VILMER, E
TRAINEAU, R
BOIRON, M
NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1987, 29 (01): : 69 - 72
[5] BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA
GOLDMAN, JM
HEMATOLOGICAL ONCOLOGY, 1987, 5 (04) : 265 - 279
[6] PROGNOSTIC FACTORS OF EARLY MORTALITY AFTER BONE-MARROW TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA
ALGARA, M
VALLS, A
RUIZ, V
CARRERAS, E
SIERRA, J
GRANENA, A
REVISTA CLINICA ESPANOLA, 1994, 194 (08): : 607 - 612
[7] BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA
GOLDMAN, JM
APPERLEY, JF
JONES, L
MARCUS, R
GOOLDEN, AWG
BATCHELOR, R
HALE, G
WALDMANN, H
REID, CD
HOWS, J
GORDONSMITH, E
CATOVSKY, D
GALTON, DAG
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (04): : 202 - 207
[8] AN OVERVIEW OF BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA
BARNETT, MJ
EAVES, AC
PHILLIPS, GL
CANADIAN MEDICAL ASSOCIATION JOURNAL, 1990, 143 (03) : 187 - 193
[9] ACCESS TO BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA
SCHROEDER, SA
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12): : 823 - 823
[10] BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA
MACKINNON, S
GOLDMAN, JM
BRITISH JOURNAL OF HOSPITAL MEDICINE, 1988, 39 (03): : 226 - 230

← 1 2 3 4 5 →